From: MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response
Characteristics
n
HRM me (%)
MSP me (%)
PSQ me (%)
All patients
65
41.5
30.8
46.2
Woman
22
40.9
31.8
Man
43
41.9
30.2
48.8
Age ≥70
27
44.4
25.9
Age <70
38
39.5
34.2
47.4
Grade III
7
42.9
Grade IV
58
41.4
29.3
46.6